UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 25, 2008
SYNVISTA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-16043
|
|
13-3304550
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
221
West Grand Avenue
Montvale,
New Jersey 07645
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (201) 934-5000
___________________________________
Former
name or former address, if changed since last report
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
ITEM
5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.
(a),
(b),
(d), (e) and (f): Not applicable.
(c) On
March
25, 2008, the Audit Committee of the Board of Directors of Synvista
Therapeutics, Inc. (“Synvista” or the “Company”) named Wendy A. Milici, age 36,
as the Company’s principal financial officer. Ms. Milici receives an annual base
salary of $125,000 per year and is eligible to receive an
annual
performance-based cash bonus
of 20%
of her base salary upon the achievement
of certain performance goals.
Ms.
Milici joined Synvista in November 2004 and serves as the Company’s director of
finance and administration, responsible for preparing operating budgets and
forecasts, coordinating the audit process, negotiating consulting agreements,
confidential disclosure agreements and material transfer agreements, and
preparing and coordinating the Company’s filings with the Securities and
Exchange Commission, among other responsibilities. Prior to joining Synvista,
Ms. Milici was an audit administrator at AXA Financial, f/k/a The MONY Group,
beginning in 1998, where she was responsible for the development of the
company’s budget and the preparation of audit committee materials. From 1993 to
1998, Ms. Milici was a senior analyst and project coordinator at Solomon
Brothers. She also was a lead assistant in the loan syndication department
at JP
Morgan from 1991 to 1993. Ms. Milici holds a Bachelor of Science, magna
cum laude,
from
Caldwell College and will receive her Masters in Business Administration from
Caldwell College in December 2008.
There
is
no family relationship between Ms. Milici and any director, executive officer,
or person nominated or chosen by Synvista to become a director or executive
officer. In addition, there are no transactions between Synvista and Ms. Milici
or any member of Ms. Milici’s immediate family of the type set forth in Item
404(a) of Regulation S-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
SYNVISTA
THERAPEUTICS, INC.
|
|
|
|
|
Dated:
March 26, 2008
|
/s/
Noah Berkowitz
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
President
and Chief Executive Officer
|